









市场行情
/
股票
/
nasdaq-alt
/

Altimmune Inc

ALT

3.860USD

-0.120-3.02%

收盘 12/26, 16:00（美东）报价延迟15分钟

369.01M总市值

亏损市盈率 TTM



Altimmune Inc

3.860

-0.120-3.02%

概览公司财务分析

概览

公司

财务

分析

关于 Altimmune Inc 公司

Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Altimmune Inc简介



公司代码ALT

公司名称Altimmune Inc

上市日期Oct 06, 2005

CEODurso (Jerome Benedict)

员工数量59

证券类型Ordinary Share

年结日Oct 06

公司地址910 Clopper Road

城市GAITHERSBURG

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编20878-1361

电话12406541450

网址https://altimmune.com/

公司代码ALT

上市日期Oct 06, 2005

CEODurso (Jerome Benedict)

Altimmune Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Vipin K. Garg, Ph.D.

Director

355.08K

Mr. Raymond M. (Ray) Jordt

Chief Business Officer

36.27K

+3.92%

Dr. Mitchel B. (Mitch) Sayare, Ph.D.

Independent Director

26.36K

Mr. Gregory L. (Greg) Weaver

Chief Financial Officer

23.08K

+130.78%

Brig. Gen. (Retd.) Klaus O. Schafer, M.D.

Independent Director

9.18K

Dr. Catherine Angell Sohn, Pharm.D.

Independent Director

1.00K

Ms. Linda M. Richardson

Chief Commercial Officer

Mr. Philip L. Hodges

Independent Director

Mr. Jerome Benedict (Jerry) Durso

Chairman of the Board, President, Chief Executive Officer

Dr. M. Scot Roberts, Ph.D.

Chief Scientific Officer

名称

名称/职务

职务

持股

持股变动

Dr. Vipin K. Garg, Ph.D.

Director

355.08K

Mr. Raymond M. (Ray) Jordt

Chief Business Officer

36.27K

+3.92%

Dr. Mitchel B. (Mitch) Sayare, Ph.D.

Independent Director

26.36K

Mr. Gregory L. (Greg) Weaver

Chief Financial Officer

23.08K

+130.78%

Brig. Gen. (Retd.) Klaus O. Schafer, M.D.

Independent Director

9.18K

Dr. Catherine Angell Sohn, Pharm.D.

Independent Director

1.00K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

6.11%

BlackRock Institutional Trust Company, N.A.

5.56%

State Street Investment Management (US)

3.45%

Two Sigma Investments, LP

3.30%

Tang Capital Management, LLC

2.04%

其他

79.53%

持股股东

占比

The Vanguard Group, Inc.

6.11%

BlackRock Institutional Trust Company, N.A.

5.56%

State Street Investment Management (US)

3.45%

Two Sigma Investments, LP

3.30%

Tang Capital Management, LLC

2.04%

其他

79.53%

股东类型

持股股东

占比

Investment Advisor

18.59%

Hedge Fund

9.67%

Investment Advisor/Hedge Fund

8.98%

Research Firm

2.85%

Individual Investor

0.65%

Bank and Trust

0.36%

Insurance Company

0.03%

Pension Fund

0.03%

其他

58.85%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

397

42.20M

45.25%

+62.13K

2025Q3

414

42.28M

51.76%

+3.92M

2025Q2

414

38.35M

59.50%

-499.87K

2025Q1

418

38.87M

69.79%

-15.45M

2024Q4

424

41.24M

78.28%

+1.10M

2024Q3

424

40.14M

86.96%

-2.89M

2024Q2

422

42.99M

89.21%

-1.89M

2024Q1

404

45.12M

79.71%

-11.40M

2023Q4

374

33.97M

69.19%

+3.12M

2023Q3

355

30.89M

106.90%

-4.84M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

5.17M

5.85%

+772.36K

+17.57%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.75M

6.52%

+223.90K

+4.05%

Jun 30, 2025

State Street Investment Management (US)

2.75M

3.12%

-637.93K

-18.81%

Jun 30, 2025

Two Sigma Investments, LP

584.60K

0.66%

-827.52K

-58.60%

Jun 30, 2025

Tang Capital Management, LLC

2.75M

3.12%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.93M

2.19%

+229.00K

+13.42%

Jun 30, 2025

Susquehanna International Group, LLP

1.62M

1.84%

+543.68K

+50.53%

Jun 30, 2025

Citadel Advisors LLC

523.46K

0.59%

+523.46K

Jun 30, 2025

Morgan Stanley & Co. LLC

533.42K

0.6%

+194.01K

+57.16%

Jun 30, 2025

Knoll Capital Management, LLC

1.12M

1.27%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Invesco NASDAQ Future Gen 200 ETF

0.57%

Virtus LifeSci Biotech Clinical Trials ETF

0.38%

State Street SPDR S&P Biotech ETF

0.15%

Fidelity Enhanced Small Cap ETF

0.09%

Direxion Daily S&P Biotech Bull 3X Shares

0.09%

iShares Micro-Cap ETF

0.06%

ProShares Ultra Nasdaq Biotechnology

0.04%

iShares Biotechnology ETF

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

iShares Russell 2000 Growth ETF

0.02%

Invesco NASDAQ Future Gen 200 ETF

占比0.57%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.38%

State Street SPDR S&P Biotech ETF

占比0.15%

Fidelity Enhanced Small Cap ETF

占比0.09%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.09%

iShares Micro-Cap ETF

占比0.06%

ProShares Ultra Nasdaq Biotechnology

占比0.04%

iShares Biotechnology ETF

占比0.03%

Invesco Nasdaq Biotechnology ETF

占比0.03%

iShares Russell 2000 Growth ETF

占比0.02%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Altimmune Inc的前五大股东是谁？



Altimmune Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：5.17M，占总股份比例：5.85%。
BlackRock Institutional Trust Company, N.A.持有股份：5.75M，占总股份比例：6.52%。
State Street Investment Management (US)持有股份：2.75M，占总股份比例：3.12%。
Two Sigma Investments, LP持有股份：584.60K，占总股份比例：0.66%。
Tang Capital Management, LLC持有股份：2.75M，占总股份比例：3.12%。